Compounding snapshot: Get it now!

Semaglutide, tirzepatide, and more

Shortage Drug Compounding and GLP-1s: What you need to know

☞ On deadline? For media inquiries CLICK HERE. 

Upcoming Events

October 14-17: ISTX24: PCCA International Seminar, Houston

October 22: APC webinar with Pharmacists Mutual: Coverage, Claims, and Compounding: What You Need to Know About Your Liability Insurance

October 29: PCAC meeting on adding several bulk drug substances to the 503A Bulks List (1 of 2)

November 15-17: Personalized Medicine Certification Course 1: Endocrinology in St. Pete Beach, Fla.

December 4:  PCAC meeting on adding several bulk drug substances to the 503A Bulks List (2 of 2)

December 13: APC Board of Directors Meeting, Las Vegas

December 13-15: A4M Longevity Fest, Las Vegas

APC In the News

Medscape focuses on compounders:

Medscape is the latest news outlet to cover tirzepatide, and it focuses on APC's perspective.

Commenting on the tirzepatide announcement:

Since the FDA announced that tirzepatide is (for now) out of shortage, APC's Scott Brunner has been all over the news offering our perspective.

Talking about those legal threats:

Baseless but time-consuming lawsuit threats make compounders shy.

APC does its best in a Hill article:

The piece spends a lot of time considering misconceptions about compounded GLP-1s, but it least it included a little straight info from Scott.

Weighing in on Lilly’s tirzepatide vials:

Scott tells Medscape that actually helping patients with vial-based tirzepatide is a welcome change for Lilly.

Shortage compounding is not a loophole, Scott explains to Axios:

"It is absolutely intentional policy on the part of FDA."

Scott predicts ongoing off-and-on shortages:

Don't expect brand-name GLP1s to be available long-term, he says

Tenille talks about the cost of firefighters’ lives:

The California Board of Pharmacy looked to ban glutathione, but the pushback was hard.

A quick quote from Scott in WaPo:

The Washington Post's story "Eli Lilly ramps up its fight against imitation weight-loss drugs" contains a short quote from CEO Scott Brunner.

Inside Health Policy quotes Scott (again):

In its article on Lilly's introduction of DTC discounted vials of Zepbound, IHP included a great quote from CEO Scott Brunner.

Scott on Lilly on GLP-1s on CBS:

You’ve probably seen the news that Eli Lilly will begin selling Zepbound in vials by mail. What you may have missed is that the CBS News story quoted APC CEO Scott Brunner.

We gave background to Inside Health Policy:

Inside Health Policy used APC for information in its piece “Uncertainty Looms Over Bulk Production Of Personalized GLP-1 Drugs.”

Support Compounding

Our Patrons